Charles Evan Ballantyne - Apr 10, 2023 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Chief Financial Officer
Signature
/s/ Cathy Rude, Attorney-in-Fact
Stock symbol
GANX
Transactions as of
Apr 10, 2023
Transactions value $
$0
Form type
4
Date filed
4/12/2023, 05:36 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Employee Stock Option (right to buy) Award $0 +100K $0.00 100K Apr 10, 2023 Common Stock 100K $4.79 Direct F1
transaction GANX Restricted Stock Units Award $0 +50K $0.00 50K Apr 10, 2023 Common Stock 50K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option shall vest 25% on April 10, 2024 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F3 The RSUs vest upon the board of directors' certification of the Issuer's share price reaching $10.00 per share based on the 10-day volume weighted average share price, subject to Reporting Person's continuous service through such vesting date.